INAB
IN8BIO, INC.Company Information
- Company Name
- IN8BIO, INC.
- CIK
- CIK0001740279
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- INAB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- INAB
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-09-13
- Last sale
- —
- Shares purchased (TTM)
- 227,302
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,719,110
- Shares outstanding
- 19,467,091
- Ownership
- 24.24%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 6.70%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash | 18 | 22 | 27 | 11 | 13 | 12 | 11 | 4 | 10 | 13 | 21 | 13 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 3 | 3 | 4 | ||||||
| Assets Current | 18 | 23 | 28 | 12 | 14 | 13 | 13 | 7 | 13 | - | 25 | 17 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | ||||||
| Restricted Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Finance Costs Noncurrent Net | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | - | 1 | 2 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 2 | 2 | 2 | 3 | 4 | 4 | 4 | - | 4 | 4 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Assets Noncurrent | 3 | 4 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | - | 9 | 10 | ||||||
| Assets | 22 | 26 | 32 | 17 | 19 | 20 | 21 | 16 | 22 | - | 34 | 26 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | - | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 3 | 2 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 4 | 5 | - | 5 | 5 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | ||||||
| Liabilities Noncurrent | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | - | 3 | 4 | ||||||
| Liabilities | 3 | 3 | 5 | 4 | 4 | 6 | 6 | 7 | 9 | - | 9 | 8 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Additional Paid In Capital | 169 | 169 | 169 | 149 | 148 | 141 | 136 | 124 | 122 | - | 116 | 101 | ||||||
| Retained Earnings Accumulated Deficit | -151 | -146 | -141 | -136 | -132 | -127 | -122 | -115 | -108 | - | -91 | -84 | ||||||
| Stockholders Equity | 18 | 23 | 28 | 13 | 15 | 14 | 14 | 9 | 14 | 18 | 25 | 18 | ||||||
| Liabilities And Stockholders Equity | 22 | 26 | 32 | 17 | 19 | 20 | 21 | 16 | 22 | - | 34 | 26 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | 490 | ||||||
| Common Stock Shares Issued | 10 | 10 | 10 | 5 | 4 | 3 | 2 | 2 | 2 | - | 1 | 1 | ||||||
| Shares Outstanding | 10 | 10 | 10 | 5 | 4 | 3 | 2 | 2 | 2 | - | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialIN8BIO, INC. (INAB) — SEC Financial Statements & Analysis
IN8BIO, INC. (INAB) is a biological products, (no diagnostic substances) company, incorporated in DE. IN8BIO, INC. trades on Nasdaq as: INAB. IN8BIO, INC. (INAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, IN8BIO, INC. carries a market cap of $27.45M, a P/E ratio of -1.47x, a P/B ratio of 1.49x, an enterprise value of $9.44M, and an EV/EBITDA multiple of -0.53x. On profitability, it posts a Return on Equity (ROE) of -111.11%, a Return on Assets (ROA) of -90.80%, and a Return on Invested Capital (ROIC) of -1420.08%. Per share, it reports EPS of $-0.96, diluted EPS of $-0.96, free cash flow per share of $-0.74, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -21.86% year-over-year and EPS growth of -83.47% year-over-year. On the balance sheet, it maintains a current ratio of 8.21x, a quick ratio of 7.97x, working capital of $16.24M, a debt-to-equity ratio of 0.18x, a debt ratio of 0.16, free cash flow of $-14.36M (TTM), and net debt of $-18.01M. Figures sourced from SEC EDGAR.
- Market Cap
- $27.45M
- P/E TTM
- -1.47x
- EPS TTM
- $-0.96
- P/B TTM
- 1.49x
- ROE TTM
- -111.11%
- ROA TTM
- -90.80%
- Debt To Equity
- 0.18x
- Free Cash Flow TTM
- $-14.36M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is IN8BIO, INC. in?
IN8BIO, INC. (INAB) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does INAB trade on?
IN8BIO, INC. (INAB) trades on the Nasdaq.
Where is IN8BIO, INC. incorporated?
IN8BIO, INC. is incorporated in DE.
When was IN8BIO, INC. (INAB)'s most recent SEC filing?
IN8BIO, INC. (INAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is INAB's market cap?
IN8BIO, INC. (INAB) has a market capitalization of $27.45M as of 2026-06-30.
What is INAB's EPS (earnings per share)?
IN8BIO, INC. (INAB)'s trailing twelve month EPS is $-0.96 as of 2026-06-30.
What is INAB's ROE (return on equity)?
IN8BIO, INC. (INAB)'s trailing twelve month Return on Equity (ROE) is -111.11% as of 2026-06-30.
What is INAB's ROA (return on assets)?
IN8BIO, INC. (INAB)'s trailing twelve month Return on Assets (ROA) is -90.80% as of 2026-06-30.
What is INAB's ROIC (return on invested capital)?
IN8BIO, INC. (INAB)'s trailing twelve month Return on Invested Capital (ROIC) is -1420.08% as of 2026-06-30.
What is INAB's EV/EBITDA?
IN8BIO, INC. (INAB)'s trailing twelve month EV/EBITDA is -0.53x as of 2026-06-30.